TCGA-05-5425-01A-02R-1628-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.600
- INTERFERON_ALPHA_RESPONSE+0.560
- INTERFERON_GAMMA_RESPONSE+0.520
- ALLOGRAFT_REJECTION+0.490
- IL6_JAK_STAT3_SIGNALING+0.460
- ADIPOGENESIS+0.430
- INFLAMMATORY_RESPONSE+0.430
- COMPLEMENT+0.420
- TNFA_SIGNALING_VIA_NFKB+0.390
- FATTY_ACID_METABOLISM+0.380
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.440
- WNT_BETA_CATENIN_SIGNALING-0.330
- NOTCH_SIGNALING-0.280
- MITOTIC_SPINDLE-0.260
- UV_RESPONSE_DN-0.190
- MYOGENESIS-0.110
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.090
- G2M_CHECKPOINT-0.090
- KRAS_SIGNALING_DN-0.090
- SPERMATOGENESIS-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-5152-01A-02R-1873-07 | — | — | 0.911 |
| 2 | TCGA-05-4418-01A-01R-1206-07 | — | cohortA4 | 0.903 |
| 3 | TCGA-38-4632-01A-01R-1755-07 | — | cohortA1 | 0.896 |
| 4 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.886 |
| 5 | TCGA-33-4589-01A-01R-1443-07 | — | cohortSQ1 | 0.873 |
| 6 | TCGA-35-4122-01A-01R-1107-07 | — | cohortA1 | 0.866 |
| 7 | TCGA-49-4494-01A-01R-1206-07 | — | cohortA1 | 0.863 |
| 8 | FBB4DAFD-11F1-498F-95C5-73D8B735465B | — | — | 0.857 |
| 9 | SRR1078879 | GTEX | — | 0.855 |
| 10 | SJEPD031215_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.600 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.430 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.380 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.310 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |